Johnson & Johnson raised its full-year sales forecast on Wednesday after beating estimates for second-quarter profit on strong demand for its cancer drug, Darzalex, and strength in its medical device business.
Johnson & Johnson Beats Profit Estimates On Strong Darzalex, Medtech Sales
About the Author: ryounglao
Leave A Comment